Key clinical point: Market failure is contributing to the rising costs of prescription drugs.
Major finding: If cost trends had not changed after the entry of new TNF inhibitors after 2009, the costs of etanercept, infliximab, and adalimumab in December 2016 would have been 40%-45% lower.
Study details: An interrupted time series analysis of payment data during 2006-2016 with a linear model that calculated the trends in costs that would have been expected if three new anti-TNFs had not entered the market after 2009.
Disclosures: The study was funded in part by the Myers Family Foundation and one author reported funding from the National Heart, Lung, and Blood Institute.
San-Juan-Rodriguez A et al. JAMA Intern Med. 2019 Feb 18. doi: 10.1001/jamainternmed.2018.7656